Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim West

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Alzheimer'S Research & Therapy|July 5, 2024
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's DiseaseDouglas Galasko, Martin R Farlow, Brendan P Lucey, et al.
Journal of Alzheimer'S Disease : JAD|January 30, 2023
Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's DiseaseCharisse N Winston, Oliver Langford, Natalie Levin, et al.
Toxicology and Applied Pharmacology|March 19, 2017
The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkeyHeidi A Schoenfeld, Tim West, Philip B Verghese, et al.
Diagnostics (Basel, Switzerland)|January 25, 2025
Clinical Utility of an Alzheimer's Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey StudyMark Monane, Demetrius M Maraganore, Robert M Carlile, et al.
Annals of Clinical and Translational Neurology|October 2, 2022
Comparison of plasma and CSF biomarkers in predicting cognitive declineAndrew J Aschenbrenner, Yan Li, Rachel L Henson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 30, 2022
A flexible modeling approach for biomarker-based computation of absolute risk of Alzheimer's disease dementiaSarah M Hartz, Jessica Mozersky, Suzanne E Schindler, et al.
Annals of Clinical and Translational Neurology|August 8, 2023
A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairmentMark Monane, Kim G Johnson, B Joy Snider, et al.
Molecular Neurodegeneration|May 2, 2021
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysisTim West, Kristopher M Kirmess, Matthew R Meyer, et al.
Science Translational Medicine|May 16, 2014
An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD miceYvette I Sheline, Tim West, Kevin Yarasheski, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 20, 2025
Accuracy of plasma biomarkers to detect Alzheimer's disease proteinopathy prior to dementiaKarly A Cody, Lianlian Du, Rachel L Studer, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Alzheimer'S Research & Therapy|July 5, 2024
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's DiseaseDouglas Galasko, Martin R Farlow, Brendan P Lucey, et al.
Journal of Alzheimer'S Disease : JAD|January 30, 2023
Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's DiseaseCharisse N Winston, Oliver Langford, Natalie Levin, et al.
Toxicology and Applied Pharmacology|March 19, 2017
The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkeyHeidi A Schoenfeld, Tim West, Philip B Verghese, et al.
Diagnostics (Basel, Switzerland)|January 25, 2025
Clinical Utility of an Alzheimer's Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey StudyMark Monane, Demetrius M Maraganore, Robert M Carlile, et al.
Annals of Clinical and Translational Neurology|October 2, 2022
Comparison of plasma and CSF biomarkers in predicting cognitive declineAndrew J Aschenbrenner, Yan Li, Rachel L Henson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 30, 2022
A flexible modeling approach for biomarker-based computation of absolute risk of Alzheimer's disease dementiaSarah M Hartz, Jessica Mozersky, Suzanne E Schindler, et al.
Annals of Clinical and Translational Neurology|August 8, 2023
A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairmentMark Monane, Kim G Johnson, B Joy Snider, et al.
Molecular Neurodegeneration|May 2, 2021
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysisTim West, Kristopher M Kirmess, Matthew R Meyer, et al.
Science Translational Medicine|May 16, 2014
An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD miceYvette I Sheline, Tim West, Kevin Yarasheski, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 20, 2025
Accuracy of plasma biomarkers to detect Alzheimer's disease proteinopathy prior to dementiaKarly A Cody, Lianlian Du, Rachel L Studer, et al.
Pageof 5